DUBLIN, December 1, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/9drqpv/global_cervical) has announced the addition of the "Global Cervical Cancer Market 2015-2019" report to their offering.
According to the report, cancer drugs are expensive, and some individuals cannot afford chemotherapy. Reimbursement plans such as public reimbursement programs reduce the financial burden of treatment. The reimbursement status of drugs is dynamic in nature and varies across countries. Factors such as the lack of cost-effectiveness can impede the reimbursement coverage of drugs.
There are several treatment options available for cervical cancer: surgery, radiotherapy, chemotherapy, and targeted therapy as well asprophylactic vaccines. However, these therapies are associated with adverse side effects, lengthy treatment periods, and suboptimal patient compliance.
In addition, vaccines costs are high, and the global cost of unmet needs for medicines for cervical cancer is approximately $26 million. Available therapies are not enough to cure the disease permanently, but survival rates can be exceeded. Therefore, an opportunity exists for pharma companies to develop new drugs that will address the unmet needs of the market.
Further, the report states that the therapies are expensive, and radiation therapy can itself cause other types of cancer, increasing the cost of treatment. Thus the overall cost of cervical cancer treatment is high, leading to fewer individuals opting for them, especially in developing countries in APAC, such as India and China, and EMEA.
The report forecasts the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.
Key questions answered in this report:
- What will the market size be in 2019 and what will the growth rate be?
- What are the Key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- F. Hoffmann-La Roche
Other prominent vendors:
- Advaxis Immunotherapies
- Bionor Pharma
- Dendreon Corporation
- Inovio Pharmaceuticals
- ISA Pharmaceuticals
- Otsuka Pharmaceuticals
- Profectus Biosciences
- Zeria Pharmaceuticals
- Key Market drivers
For more information visit http://www.researchandmarkets.com/research/9drqpv/global_cervical
SOURCE Research and Markets